Introduction
This report deals with comments made by President Trump in the State of the Union address in which he indicated…
Read more…
Overview
The naming of five distinguished scientists with extensive knowledge and expertise in immune-oncology to Northwest’s scientific advisory board is the…
Read more…
Report Overview
I usually start my reports with a summary and investment thesis. However, in this report I am putting this…
Read more…
Investment Thesis
Some subscribers have asked me if the failure of Rintega in the phase 3 ACT-IV trial in newly diagnosed…
Read more…
The Terms of the Juno Celgene Deal
Celgene and Juno announced a ten year collaboration for drug development using CAR-T therapy…
Read more…
Key Investment Points Stemming from ASCO
I have been going over data presented at ASCO on immune-oncology products and have been…
Read more…
Overview
An FDA advisory panel on April 30 recommended by a vote of 22 to 1 that Amgen’s cancer vaccine talimogene…
Read more…
Introduction to This Thought Piece
Emerging biotechnology stocks obviously are very hard to value on an absolute basis because they usually…
Read more…
Introduction
I have included an abstract on DCVax Direct and another on DCVax-L that will be presented in poster presentations at…
Read more…
Introduction
Adam Feuerstein just published a blog that attacks the results and conclusions drawn from the paper summarizing results from the…
Read more…
Introduction
Northwest Biotherapeutics just issued their 10-K for 2014 and I would urge everyone to read it. The purpose of this…
Read more…
Investment Overview
Linda Powers was invited to the 7th Annual Phacilitate Immunotherapy Forum in Washington D.C. to speak on the potential…
Read more…
Ms. Powers will present at 10:30 AM.
She will then participate in a discussion panel with representatives from Amgen, Roche Diagnostics,…
Read more…
Overview
Linda Powers spoke at the Biotech Showcase Conference in San Francisco on January 12, 2015. My Buy recommendation on Northwest Biotherapeutics…
Read more…
Neil Woodford, a highly respected UK portfolio manager has just invested $25 million on very favorable terms and the Company…
Read more…
UK designates DCVax-L as first drug to be considered for early access approval under recently enacted EAMS program.
Earlier this year,…
Read more…
DCVax Direct was used in a patient with stage 4 pancreatic cancer whose chemotherapy was stopped.
The patient, a Nat Geo…
Read more…
The Data Monitoring Committee (DMC) is charged with monitoring the safety and efficacy results of clinical trial. The committee and…
Read more…
One of the basic charges made against me by Richard Pearson and other short sellers is that they maintain that…
Read more…
I wrote on June 12th that NWBO stockholders may be seeing a changing in the tide of investor opinion. The…
Read more…
Purpose of Report
This report goes over recent news on the company in regard to DCVax Direct and DCVax-L and then…
Read more…
Purpose of New Financing
Northwest Biotherapeutics just announced a financing in which a single institutional investor bought $15 million of stock…
Read more…
Before I Get Into This Article, a Word to My Subscribers
I want to apologize to my subscribers for a software…
Read more…
Purpose of This Blog
The approval of DCVax-L under the hospital exemption early access program was a stunning positive in my…
Read more…
Overview
Northwest Biotherapeutics CEO Linda Powers made a presentation yesterday in which she addressed the bear case that has resulted in…
Read more…
Introduction
Please read this report very carefully. This is the first time that any systemic drug has been approved under the…
Read more…
Reason for Stock Weakness
The stock of Northwest Biotherapeutics (NWBO) has been under pressure that appears largely to have been caused…
Read more…
ImmunoCellular (IMUC.OB) has issued a press release stating that Manish Singh has resigned as CEO. He will be succeeded in…
Read more…
